PortfoliosLab logoPortfoliosLab logo
NBIX vs. MU
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NBIX vs. MU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Neurocrine Biosciences, Inc. (NBIX) and Micron Technology, Inc. (MU). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NBIX achieves a 24.87% return, which is significantly lower than MU's 243.32% return. Over the past 10 years, NBIX has underperformed MU with an annualized return of 13.85%, while MU has yielded a comparatively higher 54.18% annualized return.


NBIX

1D
-1.91%
1M
8.85%
6M
30.43%
YTD
24.87%
1Y
32.71%
3Y*
21.73%
5Y*
12.33%
10Y*
13.85%

MU

1D
-1.24%
1M
-1.65%
6M
183.94%
YTD
243.32%
1Y
687.66%
3Y*
149.71%
5Y*
66.39%
10Y*
54.18%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NBIX vs. MU - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NBIX
Neurocrine Biosciences, Inc.
24.87%3.90%3.60%10.31%40.24%-11.14%-10.83%50.53%-7.96%100.49%
MU
Micron Technology, Inc.
243.32%240.24%-0.96%71.93%-45.93%24.21%39.79%69.49%-22.84%87.59%

Correlation

The correlation between NBIX and MU is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since May 23, 1996

0.24

Fundamentals

Market Cap

NBIX:

$17.81B

MU:

$1.11T

EPS

NBIX:

$6.50

MU:

$44.42

PE Ratio

NBIX:

27.23

MU:

22.05

PEG Ratio

NBIX:

0.54

MU:

0.08

PS Ratio

NBIX:

5.87

MU:

12.33

PB Ratio

NBIX:

5.37

MU:

11.10

Total Revenue (TTM)

NBIX:

$3.10B

MU:

$90.27B

Gross Profit (TTM)

NBIX:

$3.05B

MU:

$65.51B

EBITDA (TTM)

NBIX:

$881.20M

MU:

$44.96B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NBIX vs. MU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NBIX
NBIX Risk / Return Rank: 7373
Overall Rank
NBIX Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
NBIX Sortino Ratio Rank: 7171
Sortino Ratio Rank
NBIX Omega Ratio Rank: 7171
Omega Ratio Rank
NBIX Calmar Ratio Rank: 7373
Calmar Ratio Rank
NBIX Martin Ratio Rank: 7272
Martin Ratio Rank

MU
MU Risk / Return Rank: 9999
Overall Rank
MU Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
MU Sortino Ratio Rank: 9999
Sortino Ratio Rank
MU Omega Ratio Rank: 9898
Omega Ratio Rank
MU Calmar Ratio Rank: 100100
Calmar Ratio Rank
MU Martin Ratio Rank: 100100
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NBIX vs. MU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Micron Technology, Inc. (MU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NBIXMUDifference
Sharpe ratioReturn per unit of total volatility

-8.30

Sortino ratioReturn per unit of downside risk

-3.92

Omega ratioGain probability vs. loss probability

1.20

1.69

-0.49

Calmar ratioReturn relative to maximum drawdown

1.50

23.23

-21.73

Martin ratioReturn relative to average drawdown

3.29

83.25

-79.96

NBIX vs. MU - Sharpe Ratio Comparison

The current NBIX Sharpe Ratio is 0.99, which is lower than the MU Sharpe Ratio of 9.29. The chart below compares the historical Sharpe Ratios of NBIX and MU, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NBIX vs. MU - Drawdown Comparison

The maximum NBIX drawdown since its inception was -97.21%, roughly equal to the maximum MU drawdown of -98.25%. Use the drawdown chart below to compare losses from any high point for NBIX and MU.


Loading charts...

Drawdown Indicators


NBIXMUDifference

Max Drawdown

Largest peak-to-trough decline

-97.21%

-98.25%

+1.04%

Max Drawdown (1Y)

Largest decline over 1 year

-20.90%

-30.28%

+9.38%

Max Drawdown (3Y)

Largest decline over 3 years

-42.89%

-57.63%

+14.74%

Max Drawdown (5Y)

Largest decline over 5 years

-42.89%

-57.63%

+14.74%

Max Drawdown (10Y)

Largest decline over 10 years

-46.39%

-57.63%

+11.24%

Current Drawdown

Current decline from peak

-1.91%

-19.29%

+17.38%

Average Drawdown

Average peak-to-trough decline

-43.74%

-58.07%

+14.33%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.52%

8.43%

+1.09%

Volatility

NBIX vs. MU - Volatility Comparison

The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 8.08%, while Micron Technology, Inc. (MU) has a volatility of 33.63%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than MU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NBIXMUDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.08%

33.63%

-25.55%

Volatility (6M)

Calculated over the trailing 6-month period

23.42%

62.19%

-38.77%

Volatility (1Y)

Calculated over the trailing 1-year period

31.73%

75.68%

-43.95%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

32.83%

54.75%

-21.92%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

39.03%

50.65%

-11.62%

Dividends

NBIX vs. MU - Dividend Comparison

NBIX has not paid dividends to shareholders, while MU's dividend yield for the trailing twelve months is around 0.05%.


PositionTTM20252024202320222021
MU
Micron Technology, Inc.
0.05%0.16%0.55%0.54%0.89%0.21%
NBIX
Neurocrine Biosciences, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%

Financials

NBIX vs. MU - Financials Comparison

This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Micron Technology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00B20.00B30.00B40.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026April
814.50M
41.46B
(NBIX) Total Revenue
(MU) Total Revenue
Values in USD except per share items

NBIX vs. MU - Profitability Comparison

The chart below illustrates the profitability comparison between Neurocrine Biosciences, Inc. and Micron Technology, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-40.0%-20.0%0.0%20.0%40.0%60.0%80.0%100.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026April
98.3%
84.6%
Portfolio components
NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.

MU - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Micron Technology, Inc. reported a gross profit of 35.06B and revenue of 41.46B. Therefore, the gross margin over that period was 84.6%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.

MU - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Micron Technology, Inc. reported an operating income of 33.31B and revenue of 41.46B, resulting in an operating margin of 80.4%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.

MU - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Micron Technology, Inc. reported a net income of 28.24B and revenue of 41.46B, resulting in a net margin of 68.1%.


Frequently Asked Questions


NBIX and MU have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MU has higher volatility (33.63%) compared to NBIX (8.08%). In terms of maximum drawdown, NBIX dropped -97.21% vs MU's -98.25%.

MU currently has the higher Sharpe Ratio (9.29 vs 0.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NBIX and MU

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer